Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAME: Vonjo (CTI Biopharma)
- INDICATIONS:
Primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L
- CLASS: Janus kinase (JAK) inhibitor, Janus kinase-2 inhibitor, Kinase inhibitor
- HALF-LIFE: 28 hours
- FDA APPROVAL DATE: 02/28/2022
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Clarithromycin, CYP3A4 inducers , CYP3A4 inhibitors, Rifampin - PREGNANCY: No available data on use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/21/2024
